Reduced retention of Pittsburgh compound B in white matter lesions

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 42, Issue 1, 2015, Pages 97-102

  Glodzik, Lidia ^a   Rusinek, Henry ^a   Li, Jinyu ^a   Zhou, Cyrus ^a   Tsui, Wai ^a   Mosconi, Lisa ^a   Li, Yi ^a   Osorio, Ricardo ^a   Williams, Schantel ^a   Randall, Catherine ^a   Spector, Nicole ^a   McHugh, Pauline ^a   Murray, John ^a   Pirraglia, Elizabeth ^a   Vallabhajolusa, Shankar ^b   de Leon, Mony ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Healthy elderly; Pittsburgh compound B; White matter; White matter lesions

Indexed keywords

PITTSBURGH COMPOUND B; 2-(4'-(METHYLAMINO)PHENYL)-6-HYDROXYBENZOTHIAZOLE; ANILINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; THIAZOLE DERIVATIVE;

ADULT; AGING; ARTICLE; BRAIN SIZE; BRAIN TISSUE; CONTROLLED STUDY; DRUG RETENTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; WHITE MATTER LESION; AGED; AMYLOID PLAQUE; BRAIN; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING; WHITE MATTER;

AGED; ANILINE COMPOUNDS; BRAIN; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THIAZOLES; WHITE MATTER;

EID: 84912019005     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-014-2897-1     Document Type: Article

References (17)

1. Klunk WE, Engler H, Nordberg A, Yanming W, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimer’s disease with Pittsburgh compound-B. Ann Neurol. 2004;55(3):306–19.
2. Fodero-Tavoletti MT, Rowe CC, McLean CA, Leone L, Li Q-X, Masters CL, et al. Characterization of PiB binding to white matter in Alzheimer disease and other dementias. J Nucl Med. 2009;50:198–204.
3. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, et al. Imaging β-amyloid burden in aging and dementia. Neurology. 2007;68(20):1718–25.
4. Stankoff B, Freeman L, Aigrot MS, Chardain A, Dolle F, Williams A, et al. Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl-11C]-2-(4'-methylaminophenyl)- 6-hydroxybenzothiazole. Ann Neurol. 2011;69(4):673–80.
5. Faria D de P, Copray S, Sijbesma JW, Willemsen AT, Buchpiguel CA, Dierckx RA, et al. PET imaging of focal demyelination and remyelination in a rat model of multiple sclerosis: comparison of [11C]MeDAS, [11C]CIC and [11C]PIB. Eur J Nucl Med Mol Imaging. 2014;41:995–1003.
6. Gouw AA, Seewann A, van der Flier WM, Barkhof F, Rozemuller AM, Scheltens P, et al. Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry. 2011;82:126–35.
7. Bech P, Kastrup M, Rafaelsen OJ. Mini-compendium of rating scales for states of anxiety depression mania schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr Scand Suppl. 1986;326:1–37.
8. Mikheev A, Nevsky G, Yitta S, Grosmann R, Rusinek H. Fully automated segmentation of the brain from T1-weighted MRI using bridge burner algorithm. J Magn Reson Imaging. 2008;27(6):1235–41.
9. Rusinek H, Glodzik L, Mikheev A, Zanotti A, Li Y, de Leon M. Fully automatic segmentation of white matter lesions: error analysis and validation of a new tool. Int J CARS. 2013;8 Suppl 1:289–91.
10. Sachdev P, Chen X, Wen W. White matter hyperintensities in mid-adult life. Curr Opin Psychiatry. 2008;21:268–74.
11. Muller-Gartner HW, Links JM, Prince JL, Bryan RN, McVeigh E, Leal JP, et al. Measurement of radiotracer concentration in brain gray matter using positron emission tomography: MRI-based correction for partial volume effects. J Cereb Blood Flow Metab. 1992;12:571–83.
12. Grimmer T, Faust M, Auer F, Alexopoulos P, Forstl H, Henriksen G, et al. White matter hyperintensities predict amyloid increase in Alzheimer’s disease. Neurobiol Aging. 2012;33:2766–73.
13. Provenzano FA, Muraskin J, Tosto G, Narkhede A, Wasserman BT, Griffith EY, et al. White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease? JAMA Neurol. 2013;70:455–61. doi:10.1001/jamaneurol.2013.1321.
14. Noh Y, Seo SW, Jeon S, Lee JM, Kim JH, Kim GH, et al. White matter hyperintensities are associated with amyloid burden in APOE4 non-carriers. J Alzheimers Dis. 2014;40(4):877–86.
15. Harauz G, Ishiyama N, Hill CM, Bates IR, Libich DS, Fares C. Myelin basic protein-diverse conformational states of an intrinsically unstructured protein and its roles in myelin assembly and multiple sclerosis. Micron. 2004;35(7):503–42.
16. Murray ME, Vemuri P, Preboske GM, Murphy MC, Schweitzer KJ, Parisi JE, et al. A quantitative postmortem MRI design sensitive to white matter hyperintensity differences and their relationship with underlying pathology. J Neuropathol Exp Neurol. 2012;71:1113–22.
17. Hong YT, Veenith T, Dewar D, Outtrim JG, Mani V, Williams C, et al. Amyloid imaging with carbon 11C-labeled Pittsburgh compound B for traumatic brain injury. JAMA Neurol. 2014;71(1):23–31.